drugset
drugset / Trial / NCT04227938

ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD

NCT04227938 ↗

Phase 1 Terminated 1 enrolled Alpine Immune Sciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The Balance study will assess the safety, tolerability, and efficacy of an investigational drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).

Timeline

Start
2020-05-11
Primary completion
2020-05-21
Completion
2020-05-21

Outcome

Outcome not reported

Stopped (Business): “Change in sponsor strategy”

Drugs

EvaluationDrugModalityDoseRoute
Subject ACAZICOLCEPT Protein / enzyme biologic — Intravenous

Indications

acute graft versus host disease